Lenvatinib/Everolimus Approved for Use in Advanced Kidney Cancer After Antiangiogenic Therapy

被引：0
|
作者：
Schuyler, Devon
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2016年 / 14卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：416 / 416
页数：1
相关论文
共 50 条
  • [21] Myopodin methylation is a prognostic biomarker and predicts antiangiogenic response in advanced kidney cancer
    Pompas-Veganzones, N.
    Sandonis, V.
    Perez-Lanzac, Alberto
    Beltran, M.
    Beardo, P.
    Juarez, A.
    Vazquez, F.
    Cozar, J. M.
    Alvarez-Ossorio, J. L.
    Sanchez-Carbayo, Marta
    TUMOR BIOLOGY, 2016, 37 (10) : 14301 - 14310
  • [22] Noninfectious Pneumonitis after Everolimus Therapy for Advanced Renal Cell Carcinoma
    White, Dorothy A.
    Camus, Philippe
    Endo, Masahiro
    Escudier, Bernard
    Calvo, Emiliano
    Akaza, Hideyuki
    Uemura, Hirotsugu
    Kpamegan, Euloge
    Kay, Andrea
    Robson, Matthew
    Ravaud, Alain
    Motzer, Robert J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2010, 182 (03) : 396 - 403
  • [23] Combination therapy for advanced and metastatic kidney cancer
    Chung-Han Lee
    Robert J. Motzer
    Nature Reviews Urology, 2019, 16 : 77 - 78
  • [24] Combination therapy for advanced and metastatic kidney cancer
    Lee, Chung-Han
    Motzer, Robert J.
    NATURE REVIEWS UROLOGY, 2019, 16 (02) : 77 - 78
  • [25] Successful resection after first-line lenvatinib therapy in an advanced thymic carcinoma
    Shimura, Masatoshi
    Miura, Kentaro
    Koizumi, Tomonobu
    Kanda, Shintaro
    Mishima, Shuji
    Hara, Daisuke
    Matsuoka, Shunichiro
    Eguchi, Takashi
    Hamanaka, Kazutoshi
    Uehara, Takeshi
    Shimizu, Kimihiro
    THORACIC CANCER, 2023, 14 (17) : 1640 - 1643
  • [26] Immunosuppresant everolimus improves progression-free survival in advanced kidney cancer patients
    不详
    ONCOLOGY-NEW YORK, 2008, 22 (07): : 841 - 841
  • [27] Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer
    Manegold, Philipp C.
    Paringer, Carmen
    Kulka, Ulrike
    Krimmel, Klaus
    Eichhorn, Martin E.
    Wilkowski, Ralf
    Jauch, Karl-Walter
    Guba, Markus
    Bruns, Christiane J.
    CLINICAL CANCER RESEARCH, 2008, 14 (03) : 892 - 900
  • [28] Combination of antiangiogenic therapy using the mTOR-inhibitor everolimus and low-dose chemotherapy for locally advanced and/or metastatic pancreatic cancer: a dose-finding study
    Joka, Mareile
    Boeck, Stefan
    Zech, Christoph J.
    Seufferlein, Thomas
    von Wichert, Goetz
    Licht, Thomas
    Krause, Annekatrin
    Jauch, Karl-Walter
    Heinemann, Volker
    Bruns, Christiane J.
    ANTI-CANCER DRUGS, 2014, 25 (09) : 1095 - 1101
  • [29] Everolimus in metastatic renal cell cancer after sunitinib/sorafenib: a new standard for kidney cancer
    Massard, Christophe
    Bay, Jacques-Olivier
    BULLETIN DU CANCER, 2009, 96 (03) : 256 - 256
  • [30] Combination of antiangiogenic and systemic therapy in advanced non-small cell lung cancer: before and after progression to leptomeningeal metastasis
    Xiao-dan Zhu
    Re-ha-ti Amanjiaoer
    Yan-li Shen
    Na Li
    Mi-hray Abdurazik
    Chun-ling Liu
    Gang Sun
    Scientific Reports, 15 (1)
12345